Summit Securities Group’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-65
Closed -$5.97K 619
2024
Q3
$6K Buy
+65
New +$6.34K ﹤0.01% 414
2024
Q2
Sell
-5,000
Closed -$461K 563
2024
Q1
$461K Sell
5,000
-2,000
-29% -$187K 0.08% 99
2023
Q4
$665K Sell
7,000
-6,400
-48% -$598K 0.06% 164
2023
Q3
$1.25M Buy
+13,400
New +$1.24M 0.13% 84

Other funds holding AMED

Summit Securities Group's AMED Position: Q4 2024 in Review

Summit Securities Group sold out of Amedisys (AMED) in Q4 2024, closing a stake of 65 shares — an estimated $5.97K sold.

Summit Securities Group first reported a position in AMED in Q3 2023 and held it in 4 quarters. The position peaked at $1.25M in Q3 2023. 290 funds tracked by Wall St. Rank hold AMED as of Q4 2024.

  • Summit Securities Group reported no remaining Amedisys position as of Q4 2024 after selling out during the quarter.
  • Summit Securities Group sold 65 Amedisys shares in Q4 2024, an estimated $5.97K.
  • Summit Securities Group first reported a position in Amedisys in Q3 2023 and held it in 4 quarters.
  • Summit Securities Group's Amedisys position peaked at $1.25M in Q3 2023.
  • 290 funds tracked by Wall St. Rank held Amedisys as of Q4 2024.

Based on Summit Securities Group's 13F filing for Q4 2024, filed 12 Feb 2025.